Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma
Status:
Not yet recruiting
Trial end date:
2024-10-20
Target enrollment:
Participant gender:
Summary
Through open-label, single-center, randomised clinical trials, we intend to demonstrate that
PD-1 treatment added to salvage surgery could further decrease the rate of disease
progression and improve the survival outcome of patients with locally recurrent
nasopharyngeal carcinoma compared with those treated with salvage surgery alone.